66 results about "Affected site" patented technology

Arrangements for collecting, analyzing, consolidating and delivering consolidated and enhanced data from a plurality of sources relating to a current event, to a third party, and reserving the consolidated and enhanced data for internal use so as to create a commercial proactive emergency management and disaster response information system that can also be used for emergent commercial purposes. A data capture device associated with an individual or a location captures data related to a current event or affected site. Incoming data may include raw data, repackaged data, or value-added data from source inputs. Captured data is sent to a centralized command center or distributed command centers where it is analyzed, resolved, correlated and repackaged for use by other parties.

The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.

The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airnvays distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.

Available quadrature amplitude modulation (“QAM”) carriers transmittable by a base station to customer sites are substantially equally divided among the sites according to the expected quality of reception. ARQ transmissions from the sites are monitored as a measure of the quality of signals received by the sites. If the quality of received signals is unacceptable, the affected site is re-assigned to a higher quality QAM. In addition, if the quality of received signals is too high, the affected site is re-assigned to a lower quality QAM.

Methods of treating tumors, lesions, and cancers comprising delivering to the affected site a combination of peroxide and hypochlorite anion. Hydrogen peroxide and sodium hypochlorite are possible sources of peroxide and hypochlorite anion, respectively. The reactants may be injected simultaneously or sequentially, and combine at the site to produce singlet oxygen. Singlet oxygen may be delivered to the treatment site or generated at the treatment site. Isotopes are also synergistically used in conjunction with singlet oxygen. The isotopes may be radioactive isotopes, non-radioactive isotopes, or both.

Provided are a skin patch sheet including a carrier sheet, an adhesive patch and a release liner laminated in this order, in which (a) the adhesive patch includes two layers, namely, a backing and an adhesive layer having the same shape; (b) the carrier sheet is adjacent to the backing of the adhesive patch; (c) the skin patch sheet includes a grip section and a body section; (d) in the body section or the body section and grip section, the area of the release liner is larger than the area of the adhesive patch; (e) the boundary between the grip section and the body section is a slit line formed by a slit; and (f) the slit extends from the side of the release liner, penetrating into the adhesive patch, up to a depth in the range of greater than or equal to 20% and less than 50% of the thickness on the adhesive patch side of the carrier sheet; a skin patch sheet in which plural sheets of adhesive patches on which carrier sheets are laminated are formed in a parallel arrangement on a release liner; use of the skin patch sheet by attaching the skin patch sheet to the skin surface in order to prevent direct scratching of an affected site of the skin, or by attaching the skin patch sheet to the face for a lift-up effect; and a method for attaching the skin patch sheet.

The invention relates to a medical endoscope laser minimally invasive surgical device with controllable energy density, comprising that laser generated by the laser light source is coupled into an optical fiber by a laser coupling part, the optical fiber is arranged in a control device for decisive range and position of emergent light, the control device for decisive range and position of emergent light is arranged at the opening of a medical endoscope by an interface part of the medical endoscope and electrically connected with a man-computer I / O system by a whole machine control system, and a power supply supplies power for a whole machine; a cooling system cools the laser source, the man-computer I / O system provides the man-computer interaction function, and the laser coupling part is electrically connected with the whole machine control system; a comprehensive control system can lead the instantaneous energy density of the laser which is acted on the affected site to achieve the preset value by controlling and coordinating the laser source and two parts of the control device for decisive range and position of emergent light.

A method and system for programming an implantable therapeutic stimulation device sensing from and delivering therapeutic stimulations to multiple sites within a patient under a plurality of programmable parameters. The method includes automatically determining which parameters need to be programmed, graphically indicating specific parameters that need to be programmed in a spatial correspondence to the affected sites in the patient and / or displaying a waveform corresponding to expected physiological activity with the programming, and providing control inputs to program the specific parameters. The method can also include automatically evaluating the programmed parameters, and if errors exist in the programming, indicating the errors and awaiting corrective input, else programming the implantable device. The method can also include automatically determining a number of sensing and stimulation electrodes connected to the device.

The invention belongs to the technical field of biomedical materials, and particularly relates to a preparation method and an application of a sustained-release system of anti-inflammatory medicaments and growth factors; a nanofiber drug loaded film prepared by the method is applicable to postoperative adhesion prevention and inflammation resistance, and skin tissue engineering stents. As a postoperative adhesion preventing film, the product has biodegradability and good biocompatibility, and can prevent postoperative inflammatory response through the controlled release of anti-inflammatory medicaments; meanwhile, through the combination of the medicaments with growth factors, the product can be used in skin tissue engineering, not only prevents inflammatory response at affected sites, but also releases growth factors to promote the regeneration and healing of skin cells. The nanofiber drug loaded film preparation method has a simple process and good controllability, and has wide application prospects in the fields of postoperative adhesion prevention and inflammation resistance, as well as skin tissue engineering.

The present invention provides a method and novel devices for treating tracheobronchitis and pneumonia in the intubated patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In a preferred embodiment, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The devices eliminate the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.

A nanoparticle containing a low-molecular-weight drug having a negatively charged group is provided that is effectively targeted to an affected site, is capable of sufficiently sustained release of the drug, and has a reduced tendency to accumulate in the liver to cause reduced side effects. The nanoparticle containing a low-molecular-weight drug having a negatively charged group is obtained by hydrophobicizing the low-molecular-weight drug having a negatively charged group with a metal ion, and reacting the hydrophobicized drug with poly L-lactic acid or poly(L-lactic acid / glycolic acid) copolymer and poly DL- or L-lactic acid-polyethylene glycol block copolymer or poly(DL- or L-lactic acid / glycolic acid)-polyethylene glycol block copolymer.

Compositions for treating or controlling infections comprise a fluoroquinolone having Formulae I-VIII and have a pH in the range from about 3.5 to about 5.5 or from about 10.5 to about 12. Methods for treating or controlling such infection use such compositions. Such compositions and methods can deliver a higher amount of the fluoroquinolone to the affected site.

The present invention is a self-expanding stent delivered to the affected site within the human body with a guide wire and hand-manipulable control apparatus. The stent is capable of full expansion only along a pre-determined length of its body with the remainder of the overall length tapering (in substantially conical form) to a fixed connection point with the guide wire. The stent is delivered to the affected area in a covering sheath that has a tip that is capable of penetrating a blockage or obstruction in a vessel such that the stent can be exposed to begin its expansion. Once the obstruction has been opened, the stent can be recaptured or retrieved by pulling it back into the sheath, collapsing the expanded stent, and withdrawing the stent and wire completely from the vessel. The present invention may be coated with a variety of therapeutic agents to aid in the treatment of the damaged tissue.

The present invention provides an improved method and novel devices for treating tracheobronchitis, bronchiectasis and pneumonia in the intubated patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The devices eliminate the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.

A pharmaceutical composition for relieving the itch, pain, and swelling resulting from insect bites and stings, and methods for producing and using the composition. The method preferably comprises topically applying to the affected area the composition which contains an abrasive ingredient and an anti-itch enzyme, both of which are dispersed in a carrier containing effective amounts of emulsifiers, and / or dispersants and may take the form of a powder, liquid, or paste. The final pharmaceutical composition is preferably made in the form of a cream or lotion so that it can be rubbed directly on the skin at the affected site. The pharmaceutical composition for relieving the itch, pain, and swelling resulting from insect bites and stings disclosed herein may also contain an anesthetic and / or antibiotic.

It is an object of the present invention to provide a means which can increase the residence property at an affected site of a dental therapeutic agent such as a therapeutic agent for periodontal disease when such agent is applied to the affected site, and also can suppress the diffusion of the agent. The present invention provides a light-emitting device for medical use that is composed of resin comprising illuminant or fluorescence substance.

The invention is a method for the treatment of mammalian articular cartilage disorders, inflammatory joint disease, trauma-related cartilage injuries, and degenerative disc disease. The method involves treating the affected area with a composition containing a therapeutically effective dose of Centella extract. The composition is delivered locally by parenteral administration to the affected site.

The invention discloses a plaster for treating ankylosing spondylitis and a preparation method thereof. The plaster disclosed by the invention contains more than forty kinds of traditional Chinese medicine ingredients, such as angelica, radix paeoniae alba, radix achyranthis bidentatae, rhizoma drynariae, salted rhizoma cibotii, eucommia bark, curculigo rhizome, fleece-flower root, morinda root, ligustrum lucidum, prepared rehmannia root, epimedium and deer-horn glue. The plaster disclosed by the invention is convenient to prepare, convenient to use, safe in clinical application, high in effective ingredient absorption, good in medicine property exertion and remarkable in treatment effect, directly reaches the affected site during external application, treats both symptoms and root causes and does not stimulate the internal organs. Through combining all the ingredients, the treatment effect is improved, the medicine property is changed or mitigated, and the toxicity and side effects of the drug are reduced or eliminated; the traditional Chinese medicine plaster disclosed by the invention is specially used for treating ankylosing spondylitis and has a relatively good symptom treatment or alleviation effect on the treatment of ankylosing spondylitis, and during the treatment of 71 patients in all, the total effective rate reaches 96%. In addition, the plaster disclosed by the invention contains camphor, plum borneol and the like, so that the corticosteroid transdermal capability can be increased by 8-10 times.

The present invention provides an improved method and novel devices for treating tracheobronchitis, bronchiectasis and pneumonia in the intubated patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The devices eliminate the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.

The bioinjection device has a housing including a pistol grip and an elongated barrel. A trigger is pivotally mounted to the housing. A plunger and needle are slidable between a first position in which the plunger and needle are slidably disposed in the barrel and a second position in which the plunger and needle extend from an opening in the end of the barrel. A retaining member is disposed about the opening at the end of the barrel. A spring-biased actuation mechanism connects the trigger with the plunger and needle. A membranous cartridge containing bone morphogenic protein, antibiotics, and / or other medication is loaded into the retaining member. A surgeon can inject the cartridge into a bone fracture or degenerative bone tissue during surgery to deliver the medicament directly to the affected site.

The present invention relates to a method for treatment of a pathology-affected site in a subject, the method comprising providing said site with a net electrical charge for a period of time by subjecting the subject to a flux of ionized gas molecules whereby is provided an electrical current between said site and tissue outside said site.

To provide a bandage pad for chemical peels that is designed to be stuck on the skin so that the condition of the skin is visually checked while the bandage pad is staying on the skin. A bandage pad for chemical peels comprises a transparent silicone film backing and a chemical peeling agent spread over the entire surface of one side of the film backing. Grooves are formed in the surface of the film backing in both vertical and horizontal directions to define a matrix of small divisions. The divisions are easily separable from each other. When undesirable reactions are observed on the skin, only the division corresponding to the affected site of the skin can be removed immediately.

Disclosed herein are materials and methods suitable for treating sites of pathological angiogenesis and abnormal neovascularization. Sites of pathological angiogenesis or abnormal neovascularization can be treated by contacting a surface at or adjacent or in the vicinity of an area of pathological angiogenesis or abnormal neovascularization with an implantable material. The implantable material comprises a biocompatible matrix and cells and is in an amount effective to treat the affected site. The composition can be a flexible planar material or a flowable composition. Diseases susceptible to treatment with the present invention include, for example, macular degeneration, rheumatoid arthritis, psoriasis, psoriatic arthritis, systemic inflammatory diseases, and treatment of tumors by surgical resection, radiation therapy or chemotherapy.

The invention relates to an external application Chinese medicinal composition for treating cystic hyperplasia of breast. The external application Chinese medicinal composition comprises the following bulk pharmaceuticals in parts by weight: 20-2,000 parts of garden balsam stem, 4-400 parts of frankincense, 4-400 parts of myrrh, 5-480 parts of indian iphigenia bulb, 4-400 parts of cowherb seed, 4-400 parts of pangolin, 6-600 parts of honeycomb, 4-400 parts of green tangerine peel, 6-600 parts of tangerine seed and 2-120 parts of borneol. The compatibility of a Chinese medicinal formula adopted in the invention is consistent with the principle of syndrome differentiation and treatment of cystic hyperplasia of breast. In a treatment method, the external application Chinese medicinal composition is mainly used for dispersing the depressed liver-energy, relieving pain, invigorating blood circulation, activating the channels and eliminating stagnation. According to breast nodule powder in a prescription, and the treatment principle of intramammary nodules includes promoting qi circulation, removing obstruction, reducing phlegm, resolving masses, dissolving stasis and relieving pain, and is just matched with the pathogenesis of intramammary nodules. Through external application, the medicament can permeates into a human body through pores, plays a role in clearing and activating thechannels and collaterals, and directly reaches an affected site, so that a treatment effect is achieved.

An object of the present invention is to provide a therapeutic agent for ulcerative colitis which allows 5-aminosalicylic acid (5-ASA) useful as a therapeutic agent for ulcerative colitis to be efficiently delivered to the large intestine of the affected site almost without being absorbed or metabolized in the stomach or the upper part of the small intestine and is safe and can be administered over a long term. The present invention relates to 5-ASA into which D-galactose represented by the following general formula [1] has been introduced. The compound of the present invention can be efficiently delivered to the large intestine of the site of action, and is degraded by the intestinal bacterial flora, whereby 5-ASA as the active ingredient can be produced in the large intestine.

Compositions for treating or controlling infections comprise a fluoroquinolone having Formulae I-VIII and have a pH in the range from about 3.5 to about 5.5 or from about 10.5 to about 12. Methods for treating or controlling such infection use such compositions. Such compositions and methods can deliver a higher amount of the fluoroquinolone to the affected site.

The invention relates to a desloratadine external preparation and a preparation method thereof. The external preparation takes desloratadine as a main drug and is used for treating allergic skin inflammation. The desloratadine external preparation can increase the concentration of free drug in skin local tissues of the part with the allergic skin inflammation of a body through percutaneous absorption, have an effective histamine sensitization antagonism role, better play local antianaphylaxis and anti-inflammation efficacies and reduce adverse reactions. The external formulation does not pass through the gastrointestinal tract, thereby avoiding the first pass effect and reduce the probability of occurrence of adverse reactions. The external preparation can be directly applied at the affected side, and the onset of action is rapid. Furthermore, the dose and the coverage area of the external preparation can be selected according to the area and the severity of the affected site, and the external preparation is convenient to use and convenient to carry.

Methods for alleviating osteoarthritis-associated symptoms by selecting a treatment-eligible patient and local administration of a clostridial derivative, such as a botulinum toxin, to an osteoarthritis-affected site are disclosed herein.